Vice President
Pivotal Bioventure Partners
San Francisco California UNITED STATES
Jim Trenkle, PhD, MBA joined Pivotal in 2017. Before joining Pivotal, Jim spent 10 years at Gilead Sciences, where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy. Much of his work was in liver diseases, where he contributed to the discovery of ledipasvir and other clinical candidates for Hepatitis C (HCV). He moved out of the laboratory to direct development strategy for HCV, HBV, and liver fibrosis, leading development teams from IND through drug filings and approvals for a number of important drugs (Sovaldi®, Harvoni®, Epclusa®, Vosevi®). His most recent role at Gilead was as Associate Director of Commercial Strategy, Liver Diseases with responsibility for forecasting, market research, and global launch readiness for the liver disease portfolio. Jim earned his PhD in Organic Chemistry from the Massachusetts Institute of Technology, and his MBA from University of California, Berkeley – Walter A. Hass School of Business. Jim is a board observer at Inozyme, Fusion Pharmaceuticals, and Karuna Therapeutics, and previously at Entasis Therapeutics.
None yet.